Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Add-on tacrolimus a viable option for RA patients with insufficient abatacept response

25 Nov 2019

Use of tacrolimus (TAC) appears to be safe and effective in the management of rheumatoid arthritis (RA) patients with inadequate response to abatacept, as shown in a recent study.

The analysis included 25 abatacept-treated RA patients (mean age, 67.0 years; disease duration, 16.2 years) who received add-on TAC therapy and were followed for >24 weeks. The mean duration of abatacept treatment at TAC initiation was 1.2 years, with a mean dose of 1.2 mg/d at baseline and 1.6 mg/d at week 24. Many patients had a pulmonary comorbidity (10 patients; 40.0 percent), including six with interstitial pneumonia and four with old pulmonary tuberculosis.

Majority of the patients (84.0 percent) did not use concomitant methotrexate (MTX), the reasons for which included the following: interstitial pneumonia, pulmonary tuberculosis, bacterial pneumonia, sore throat, renal dysfunction, septic shock, physician judgment and patient preference.

There were 20 patients (80 percent) who were treated with abatacept without any concomitant conventional synthetic disease modifying antirheumatic drugs. More than half of the patients were treated with oral glucocorticoids. Mean disease activity as assessed by DAS28‐ESR score was 4.97, corresponding to moderate disease activity.

Mean Disease Activity Score of 28 joints-erythrocyte sedimentation rate decreased substantially, from 4.97 at baseline to 3.35 at week 24. The rate of low disease activity or remission was 40.0 percent, while that of moderate or good response according to the European League Against Rheumatism criteria was 72.0 percent.

Kaplan-Meier analysis showed that the abatacept retention rate was high at 92.0 percent at week 24. Only one patient discontinued TAC therapy due to an adverse event (itching sensation).

The present data indicate that TAC therapy is a viable complementary treatment option in daily clinical practice, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.